Health

Emerging Applications for Liquid Biopsy in Drug Development, Upcoming Webinar Hosted by Xtalks

Leave a comment


Due to advances in next-generation sequencing for evaluation of the human genome, comprehensive analyses of circulating tumor DNA (ctDNA) through the liquid biopsy, represents a minimally invasive means to diagnose cancer.


TORONTO, Ontario (PRWEB)

Precision oncology represents a mainstay for cancer treatment through the targeting of specific molecular and genetic alterations associated with a patient’s tumor. With the emergence of pan-solid tumor approvals for immunotherapies such as pembrolizumab and receptor kinase inhibitors such as larotrectinib, it is the biomarkers themselves rather than the individual tumor type that is predictive of response to therapy and represents an exciting time in the war on cancer. With more than 50 percent of all new therapy approvals classified as precision medicines, there is an increased need to identify patient populations most likely to benefit from therapy, as well as maximize patient access to these treatments. Due to advances in next-generation sequencing for evaluation of the human genome, comprehensive analyses of circulating tumor DNA (ctDNA) through the liquid biopsy, represents a minimally invasive means to diagnose cancer.

A liquid biopsy can detect mutations associated with treatment selection, monitor tumor evolution and predict disease recurrence or relapse. Due to the broad range of ctDNA applications, these liquid biopsy analyses enable a valuable tool to facilitate therapeutic development and expedite access to life-saving treatments for patients.

This webinar will highlight the different areas where liquid biopsy analyses are being applied in drug development today, including in advanced-stage disease for patient selection or stratification, evaluating treatment efficacy and understanding underlying genetic mechanisms of clinical response and resistance to guide future treatment strategies.

Register to learn about the emerging applications for liquid biopsy, including evaluation of molecular residual disease in early-stage cancer.

Join experts from Labcorp, Taylor Jensen (moderator), PhD, Vice President, Head of Oncology Science; and Mark Sausen, PhD, Executive Director, Head of Technology Innovation, PGDx, for the live webinar on Wednesday, October 5, 2022, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Emerging Applications for Liquid Biopsy in Drug Development.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Leave a Reply